|
INCREASED RISK OF MYOCARDIAL DEPRESSION
|
KETOCONAZOLE MAY INCREASE THE PLASMA LEVELS OF THE DRUG
|
KETOCONAZOLE MAY INCREASE THE PLASMA LEVELS OF THE DRUG
|
KETOCONAZOLE MAY INCREASE THE PLASMA LEVELS OF THE DRUG
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
PHENYTOIN ENHANCES THE DRUG METABOLISM HENCE DECREASED SERUM LEVELS HAVE BEEN OBSERVED
|
MEPROBAMATE MAY INCREASE HEPATIC METABOLISM OF THE DRUG LEADING TO DECREASED PLASMA CONCENTRATION
|
CONCURRENT USE WITH DRUGS CAUSING TORSADES PHENOMENON OR PROLONGED Q-TC INTERVAL MAY LEAD TO INCREASED CHANCES OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION HAS RESULTED IN INCREASED PROTHROMBIN TIME, WITH OR WITHOUT CLINICAL BLEEDING
|
INCREASED HYPOTENSIVE EFFECT IS SEEN
|
INCREASED HYPOTENSIVE EFFECT IS SEEN
|
RAISES THE SERUM DIGOXIN CONCENTRATION DUE TO REDUCTION IN CLEARANCE AND/OR VOLUME OF DISTRIBUTION OF THE DRUG, WITH THE IMPLICATION THAT DIGITALIS INTOXICATION MAY RESULT
|
RAISES THE SERUM DIGOXIN CONCENTRATION DUE TO REDUCTION IN CLEARANCE AND/OR VOLUME OF DISTRIBUTION OF THE DRUG, WITH THE IMPLICATION THAT DIGITALIS INTOXICATION MAY RESULT
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS ANTIARRHYTHMIC AGENTS , MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS ANTIARRHYTHMIC AGENTS , MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS ANTIARRHYTHMIC AGENTS , MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS ANTIARRHYTHMIC AGENTS , MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS ANTIARRHYTHMIC AGENTS , MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS ANTIARRHYTHMIC AGENTS , MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS ANTIARRHYTHMIC AGENTS , MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS ANTIARRHYTHMIC AGENTS , MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION MAY PRODUCE ELECTROCARDIOGRAPHIC ABNORMALITIES AND INCREASE RISK OF CONVULSIONS, IF USED IN SEVERE MALARIA, MEFLOQUINE ADMINISTRATION SHOULD BE DELAYED AT LEAST 12 HRS. AFTER THE LAST DOSE
|
QUINIDINE MAY INCREASE PLASMA CONCENTRATION OF THE DRUG
|
QUINIDINE MAY INCREASE PLASMA CONCENTRATION OF THE DRUG
|
QUINIDINE MAY INCREASE PLASMA CONCENTRATION OF THE DRUG
|
QUINIDINE MAY INCREASE PLASMA CONCENTRATION OF THE DRUG
|
QUINIDINE MAY INCREASE PLASMA CONCENTRATION OF THE DRUG
|
QUINIDINE MAY INCREASE PLASMA CONCENTRATION OF THE DRUG
|
QUINIDINE MAY INCREASE PLASMA CONCENTRATION OF THE DRUG
|
QUINIDINE MAY INCREASE PLASMA CONCENTRATION OF THE DRUG
|
QUINIDINE MAY INCREASE PLASMA CONCENTRATION OF THE DRUG
|
QUINIDINE MAY INCREASE PLASMA CONCENTRATION OF THE DRUG
|
QUINIDINE MAY INCREASE PLASMA CONCENTRATION OF THE DRUG
|
PARASYMPATHOMIMETICS EFFECTIVENESS IN MYASTHENIA GRAVIS IS REDUCED BY SOME BETABLOCKERS, ANTIARRHYTHMICS & GENERAL ANAESTHETICS
|
PARASYMPATHOMIMETICS EFFECTIVENESS IN MYASTHENIA GRAVIS IS REDUCED BY SOME BETABLOCKERS, ANTIARRHYTHMICS & GENERAL ANAESTHETICS
|
CO-ADMINISTRATION WITH ANTIPLATELET AGENTS MAY BE ASSOCIATED WITH AN INCREASE IN BLEEDING.
|
CO-ADMINISTRATION WITH ANTIPLATELET AGENTS MAY BE ASSOCIATED WITH AN INCREASE IN BLEEDING.
|
ANTICOAGULANT EFFECT IS INCREASED OF ORAL ANTICOAGULANTS
|
ANTICOAGULANT EFFECT IS INCREASED OF ORAL ANTICOAGULANTS
|
ANTICOAGULANT EFFECT IS INCREASED OF ORAL ANTICOAGULANTS
|
ANTICOAGULANT EFFECT IS INCREASED OF ORAL ANTICOAGULANTS
|
ANTICOAGULANT EFFECT IS INCREASED OF ORAL ANTICOAGULANTS
|
ANTICOAGULANT EFFECT IS INCREASED OF ORAL ANTICOAGULANTS
|
ANTICOAGULANT EFFECT IS INCREASED OF ORAL ANTICOAGULANTS
|
FLUCONAZOLE INCREASES SERUM PLASMA CONCENTRATION OF THE DRUG
|
RIFAMPICIN MAY ACCELERATES METABOLISM OF THE DRUG & MAY CAUSE DECREASED PLASMA CONCENTRATION
|
PHENOBARBITONE ENHANCES DRUG METABOLISM HENCE DECREASED SERUM LEVELS OF THE DRUG HAVE BEEN OBSERVED
|
PHENOBARBITONE ENHANCES DRUG METABOLISM HENCE DECREASED SERUM LEVELS OF THE DRUG HAVE BEEN OBSERVED
|
PHENOBARBITONE ENHANCES DRUG METABOLISM HENCE DECREASED SERUM LEVELS OF THE DRUG HAVE BEEN OBSERVED
|
PHENOBARBITONE ENHANCES DRUG METABOLISM HENCE DECREASED SERUM LEVELS OF THE DRUG HAVE BEEN OBSERVED
|
PHENOBARBITONE ENHANCES DRUG METABOLISM HENCE DECREASED SERUM LEVELS OF THE DRUG HAVE BEEN OBSERVED
|
PHENOBARBITONE ENHANCES DRUG METABOLISM HENCE DECREASED SERUM LEVELS OF THE DRUG HAVE BEEN OBSERVED
|
INCREASED SEDATIVE EFFECT
|
GATIFLOXACIN MAY HAVE THE POTENTIAL TO PROLONG THE QT INTERVAL ; CO-ADMINISTRATION WITH DRUGS KNOWN TO PROLONG QT INTERVAL SHOULD BE AVOIDED
|
THEORETICAL POTENTIAL FOR INTERACTION WITH METFORMIN BY COMPETING FOR COMMON RENAL TUBULAR TRANSPORT SYSTEM
|
THEORETICAL POTENTIAL FOR INTERACTION WITH METFORMIN BY COMPETING FOR COMMON RENAL TUBULAR TRANSPORT SYSTEM
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION MAY CAUSE PROLONGATION OF Q-T INTERVAL LEADING TO INCREASED RISK OF VENTRICULAR ARRHYTHMIAS
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION MAY CAUSE PROLONGATION OF Q-T INTERVAL LEADING TO INCREASED RISK OF VENTRICULAR ARRHYTHMIAS
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION MAY CAUSE PROLONGATION OF Q-T INTERVAL LEADING TO INCREASED RISK OF VENTRICULAR ARRHYTHMIAS
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION MAY CAUSE PROLONGATION OF Q-T INTERVAL LEADING TO INCREASED RISK OF VENTRICULAR ARRHYTHMIAS
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION MAY CAUSE PROLONGATION OF Q-T INTERVAL LEADING TO INCREASED RISK OF VENTRICULAR ARRHYTHMIAS
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION MAY CAUSE PROLONGATION OF Q-T INTERVAL LEADING TO INCREASED RISK OF VENTRICULAR ARRHYTHMIAS
|
PROLONG QT INTERVAL; CO-ADMINISTRATION WITH CLASS 1A ANTIARRHYTHMIC AGENTS SHOULD BE AVOIDED
|
PROLONG QT INTERVAL; CO-ADMINISTRATION WITH CLASS 1A ANTIARRHYTHMIC AGENTS SHOULD BE AVOIDED
|
CONCURRENT USE WITH H-1 RECEPTOR BLOCKER LIKE ASTEMIZOLE, ALTER THE METABOLISM OF ASTEMIZOLE; RARE CASES OF CARDIOVASCULAR ADVERSE EVENTS,LIKE PROLONGED QT INTERVAL, CARDIAC ARREST,TORSADE DE POINTES, AND VENTRICULAR ARRHYTHMIAS HAVE BEEN REPORTED
|
ALKALINIZATION OF URINE MAY INHIBITS ITS EXCRETION & RAISE ITS PLASMA CONCENTRATION
|
ALKALINIZATION OF URINE MAY INHIBITS ITS EXCRETION & RAISE ITS PLASMA CONCENTRATION
|
PARASYMPATHOMIMETICS EFFECTIVENESS IN MYASTHENIA GRAVIS IS REDUCED BY SOME BETABLOCKERS, ANTIARRHYTHMICS & GENERAL ANAESTHETICS
|
PARASYMPATHOMIMETICS EFFECTIVENESS IN MYASTHENIA GRAVIS IS REDUCED BY SOME BETABLOCKERS, ANTIARRHYTHMICS & GENERAL ANAESTHETICS
|
PARASYMPATHOMIMETICS EFFECTIVENESS IN MYASTHENIA GRAVIS IS REDUCED BY SOME BETABLOCKERS, ANTIARRHYTHMICS & GENERAL ANAESTHETICS
|
QUINIDINE MAY ANTAGONISE ITS EFFECT
|
HIV PROTEASE INHIBITORS MAY INCREASE PLASMA CONCENTRATION OF THE DRUG DUE TO INHIBITION OF THEIR METABOLISM WITH AN INCREASED RISK OF VENTRICULAR ARRHYTHMIAS
|
HIV PROTEASE INHIBITORS MAY INCREASE PLASMA CONCENTRATION OF THE DRUG DUE TO INHIBITION OF THEIR METABOLISM WITH AN INCREASED RISK OF VENTRICULAR ARRHYTHMIAS
|
ANTACIDS CAN DELAY & DECREASE ABSORPTION
|
CAUSE INCREASED SERUM LEVELS OF QUINIDINE BY 33%, SO REDUCE QUINIDINE DOSAGE BY ONE-THIRD
|
PROLONGATION OF QT INTERVAL MAY BE SERIOUS COMPLICATION
|
CONCURRENT ADMINISTRATION MAY CAUSE BRADYCARDIA, MYOCARDIAL DEPRESSION OR A.V. BLOCK
|
CONCURRENT ADMINISTRATION MAY CAUSE BRADYCARDIA, MYOCARDIAL DEPRESSION OR A.V. BLOCK
|
CONCURRENT ADMINISTRATION MAY CAUSE BRADYCARDIA, MYOCARDIAL DEPRESSION OR A.V. BLOCK
|
CONCURRENT ADMINISTRATION MAY CAUSE BRADYCARDIA, MYOCARDIAL DEPRESSION OR A.V. BLOCK
|
CONCURRENT ADMINISTRATION MAY CAUSE BRADYCARDIA, MYOCARDIAL DEPRESSION OR A.V. BLOCK
|
CONCURRENT ADMINISTRATION MAY CAUSE BRADYCARDIA, MYOCARDIAL DEPRESSION OR A.V. BLOCK
|
CONCURRENT ADMINISTRATION MAY CAUSE BRADYCARDIA, MYOCARDIAL DEPRESSION OR A.V. BLOCK
|
CONCURRENT ADMINISTRATION MAY CAUSE BRADYCARDIA, MYOCARDIAL DEPRESSION OR A.V. BLOCK
|
CONCURRENT ADMINISTRATION MAY CAUSE BRADYCARDIA, MYOCARDIAL DEPRESSION OR A.V. BLOCK
|
CONCURRENT ADMINISTRATION MAY CAUSE BRADYCARDIA, MYOCARDIAL DEPRESSION OR A.V. BLOCK
|
CONCURRENT ADMINISTRATION MAY CAUSE BRADYCARDIA, MYOCARDIAL DEPRESSION OR A.V. BLOCK
|
CONCURRENT ADMINISTRATION MAY CAUSE BRADYCARDIA, MYOCARDIAL DEPRESSION OR A.V. BLOCK
|
CONCURRENT ADMINISTRATION MAY CAUSE BRADYCARDIA, MYOCARDIAL DEPRESSION OR A.V. BLOCK
|
NEUROMUSCULAR BLOCKING EFFECT IS ENHANCED
|
NEUROMUSCULAR BLOCKING EFFECT IS ENHANCED
|
NEUROMUSCULAR BLOCKING EFFECT IS ENHANCED
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS INCLUDING VENTRICULAR TACHYCARDIA, FIBRILLATION, TORSADES DE POINTES & QT PROLONGATION
|
ATROPINE LIKE ANTICHOLENERGIC SIDE EFFECTS MAY POTENTIATE LEADING TO CENTRAL ANTICHILENERGIC SYNDROME
|